194 related articles for article (PubMed ID: 29877131)
1. Onabotulinumtoxin A (BOTOX®) for ProphylaCTIC Treatment of Pediatric Migraine: A Retrospective Longitudinal Analysis.
Shah S; Calderon MD; Wu W; Grant J; Rinehart J
J Child Neurol; 2018 Aug; 33(9):580-586. PubMed ID: 29877131
[TBL] [Abstract][Full Text] [Related]
2. Onabotulinumtoxin-A treatment in Greek patients with chronic migraine.
Vikelis M; Argyriou AA; Dermitzakis EV; Spingos KC; Mitsikostas DD
J Headache Pain; 2016 Dec; 17(1):84. PubMed ID: 27640152
[TBL] [Abstract][Full Text] [Related]
3. Monocentric Prospective Study into the Sustained Effect of Incobotulinumtoxin A (XEOMIN
Ion I; Renard D; Le Floch A; De Verdal M; Bouly S; Wacongne A; Lozza A; Castelnovo G
Toxins (Basel); 2018 Jun; 10(6):. PubMed ID: 29857565
[TBL] [Abstract][Full Text] [Related]
4. OnabotulinumtoxinA (BOTOX®): a review of its use in the prophylaxis of headaches in adults with chronic migraine.
Frampton JE
Drugs; 2012 Apr; 72(6):825-45. PubMed ID: 22468643
[TBL] [Abstract][Full Text] [Related]
5. Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study.
Binder WJ; Brin MF; Blitzer A; Schoenrock LD; Pogoda JM
Otolaryngol Head Neck Surg; 2000 Dec; 123(6):669-76. PubMed ID: 11112955
[TBL] [Abstract][Full Text] [Related]
6. The Use of Botulinum Toxin Type A in Medically Refractory Pediatric Patients With Chronic Daily Headaches and Its Impact on the Quality of Life.
Akbar A; Ford J; Tripathi S
J Child Neurol; 2024 Jan; 39(1-2):55-60. PubMed ID: 38351705
[No Abstract] [Full Text] [Related]
7. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
Cady R; Schreiber C
Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
[TBL] [Abstract][Full Text] [Related]
8. Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.
Winner PK; Sadowsky CH; Martinez WC; Zuniga JA; Poulette A
Headache; 2012 Sep; 52(8):1219-25. PubMed ID: 22607530
[TBL] [Abstract][Full Text] [Related]
9. Catastrophizing attitude changes after onabotulinumtoxin A treatment in chronic migraine.
Grazzi L; Grignani E; Sansone E; Raggi A; D'Amico D; Andrasik F
Neurol Sci; 2019 May; 40(Suppl 1):201-202. PubMed ID: 30859415
[No Abstract] [Full Text] [Related]
10. Onabotulinumtoxin Type A reconstitution with preserved versus preservative-free saline in chronic migraine (B-RECON). A randomised, double-blind trial.
Zidan A; Hussaini S; Gibson S; Brooks G; Mejico L
Int J Clin Pract; 2020 Sep; 74(9):e13522. PubMed ID: 32350975
[TBL] [Abstract][Full Text] [Related]
11. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.
Aurora SK; Dodick DW; Turkel CC; DeGryse RE; Silberstein SD; Lipton RB; Diener HC; Brin MF;
Cephalalgia; 2010 Jul; 30(7):793-803. PubMed ID: 20647170
[TBL] [Abstract][Full Text] [Related]
12. Botulinum toxin: A lift for chronic migraines.
Sanassi LA
JAAPA; 2016 Jun; 29(6):1-4. PubMed ID: 27228039
[TBL] [Abstract][Full Text] [Related]
13. Onabotulinumtoxin-A in Chronic Migraine: Should Timing and Definition of Non-Responder Status Be Revised? Suggestions From a Real-Life Italian Multicenter Experience.
Vernieri F; Paolucci M; Altamura C; Pasqualetti P; Mastrangelo V; Pierangeli G; Cevoli S; D'Amico D; Grazzi L
Headache; 2019 Sep; 59(8):1300-1309. PubMed ID: 31454075
[TBL] [Abstract][Full Text] [Related]
14. CGRP and PTX3 as Predictors of Efficacy of Onabotulinumtoxin Type A in Chronic Migraine: An Observational Study.
Domínguez C; Vieites-Prado A; Pérez-Mato M; Sobrino T; Rodríguez-Osorio X; López A; Campos F; Martínez F; Castillo J; Leira R
Headache; 2018 Jan; 58(1):78-87. PubMed ID: 29131327
[TBL] [Abstract][Full Text] [Related]
15. IncobotulinumtoxinA for Migraine: A Retrospective Case Series.
Kazerooni R; Lim J; Ashley Blake P; Lessig S
Clin Ther; 2015 Aug; 37(8):1860-4. PubMed ID: 26166734
[TBL] [Abstract][Full Text] [Related]
16. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.
Aurora SK; Winner P; Freeman MC; Spierings EL; Heiring JO; DeGryse RE; VanDenburgh AM; Nolan ME; Turkel CC
Headache; 2011 Oct; 51(9):1358-73. PubMed ID: 21883197
[TBL] [Abstract][Full Text] [Related]
17. Refractory chronic migraine: is drug withdrawal necessary before starting a therapy with onabotulinum toxin type A?
Butera C; Colombo B; Bianchi F; Cursi M; Messina R; Amadio S; Guerriero R; Comi G; Del Carro U
Neurol Sci; 2016 Oct; 37(10):1701-6. PubMed ID: 27395386
[TBL] [Abstract][Full Text] [Related]
18. [Botulinum toxin injections for chronic migraine in adolescents - an early therapeutic option in the transition from neuropaediatrics to neurology].
Bernhard MK; Bertsche A; Syrbe S; Weise S; Merkenschlager A
Fortschr Neurol Psychiatr; 2014 Jan; 82(1):39-42. PubMed ID: 24446117
[TBL] [Abstract][Full Text] [Related]
19. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study.
Aurora SK; Gawel M; Brandes JL; Pokta S; Vandenburgh AM;
Headache; 2007 Apr; 47(4):486-99. PubMed ID: 17445098
[TBL] [Abstract][Full Text] [Related]
20. Treatment of chronic migraine with intramuscular pericranial injections of onabotulinumtoxin a.
Belvis R; Mas N
Recent Pat CNS Drug Discov; 2014; 9(3):181-92. PubMed ID: 25643127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]